Evaluating Effectiveness and Safety in Chronic Kidney Disease with Atrial Flutter Using an Anticoagulation Strategy.

Abstract

Background and Objectives: Recent randomized trials of oral antithrombotic drugs with atrial flutter (AFL) excluded patients with renal impairment because of their increased risk of bleeding. To date, no relevant studies have assessed the effectiveness and safety of different antithrombotic drugs in chronic kidney disease (CKD) patients with AFL. This cohort study evaluated the effectiveness and safety of different antithrombotic drugs in CKD patients with AFL. This study also investigated the risk of cardiovascular events from antithrombotic drugs through different risk profiles of stroke stratified by the CHA2DS2-VASc score. Materials and Methods: This cohort study was performed in patients with AFL and CKD who were extracted from the National Health Insurance (NHI) Database in Taiwan. Oral antithrombotic therapy (oral anticoagulants (OAC) or antiplatelets (APT)) was administered to patients who had been diagnosed with AFL after being diagnosed with CKD between 2011 and 2015. Primary outcomes, including ischemic stroke, systemic embolism, and composite of stroke, and secondary outcomes, including major adverse cardiac events (MACEs), major bleeding, all-cause mortality, and cardiovascular-related death, were examined. Results: A total of 2468 patients were included in this study. The results showed no statistically significant differences in the risk of primary outcomes. For the secondary outcomes, there were also no statistically significant differences in the risk of MACEs and major bleeding. However, the pooled results indicated that the hazard ratio (HR) for all-cause mortality with OAC was 0.24 (95% confidence interval (CI) = 0.10-0.55) compared with combination therapy, and the HR for APT compared with OAC was 2.86 (95% CI = 1.48-5.53). Conclusions: In the studied population, OAC or APT alone were proved equally effective for stroke prophylaxis. Furthermore, OAC might reduce the all-cause mortality rate compared with APT and should be considered as the first choice of oral antithrombotic drugs in patients with AFL and CKD.

• Authors: Ying-Ting Wang, Chung-Yu Chen, Ming-Jong Bair
• Journal: Medicina (Kaunas, Lithuania) (Medicina (Kaunas)) Vol. 56 Issue 6 (May 28 2020) ISSN: 1648-9144 [Electronic] Switzerland
• PMID: 32481685 (Publication Type: Journal Article)

Chemical References

• Anticoagulants

Topics

• Aged
• Aged, 80 and over
• Anticoagulants (pharmacology, standards, therapeutic use)
• Atrial Flutter (drug therapy, physiopathology)
• Chi-Square Distribution
• Cohort Studies
• Female
• Humans
• Male
• Middle Aged
• Patient Safety (standards, statistics & numerical data)
• Program Evaluation (methods)
• Quality of Health Care (standards, statistics & numerical data)
• Renal Insufficiency, Chronic (drug therapy, physiopathology)
• Taiwan